GEP20115356B - Metastin derivatives and use thereof - Google Patents
Metastin derivatives and use thereofInfo
- Publication number
- GEP20115356B GEP20115356B GEAP200610770A GEAP2006010770A GEP20115356B GE P20115356 B GEP20115356 B GE P20115356B GE AP200610770 A GEAP200610770 A GE AP200610770A GE AP2006010770 A GEAP2006010770 A GE AP2006010770A GE P20115356 B GEP20115356 B GE P20115356B
- Authority
- GE
- Georgia
- Prior art keywords
- metastin derivatives
- activity
- receptor
- cancer
- metastin
- Prior art date
Links
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005370388 | 2005-12-22 | ||
| JP2006275843 | 2006-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20115356B true GEP20115356B (en) | 2011-12-26 |
Family
ID=37846230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP200610770A GEP20115356B (en) | 2005-12-22 | 2006-12-21 | Metastin derivatives and use thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7960348B2 (enExample) |
| EP (1) | EP1963362B1 (enExample) |
| JP (2) | JP4653840B2 (enExample) |
| KR (1) | KR101368607B1 (enExample) |
| AR (1) | AR058584A1 (enExample) |
| AU (1) | AU2006328333B2 (enExample) |
| BR (1) | BRPI0619399B8 (enExample) |
| CA (1) | CA2634647C (enExample) |
| CR (1) | CR10019A (enExample) |
| CY (1) | CY1112353T1 (enExample) |
| DK (1) | DK1963362T3 (enExample) |
| ES (1) | ES2375038T3 (enExample) |
| GE (1) | GEP20115356B (enExample) |
| HR (1) | HRP20110851T1 (enExample) |
| IL (1) | IL190888A (enExample) |
| JO (1) | JO2799B1 (enExample) |
| MA (1) | MA30060B1 (enExample) |
| ME (1) | ME01015B (enExample) |
| MY (1) | MY151967A (enExample) |
| NO (1) | NO341879B1 (enExample) |
| NZ (1) | NZ568322A (enExample) |
| PE (1) | PE20071141A1 (enExample) |
| PL (1) | PL1963362T3 (enExample) |
| PT (1) | PT1963362E (enExample) |
| RS (1) | RS52007B (enExample) |
| RU (1) | RU2430107C2 (enExample) |
| SI (1) | SI1963362T1 (enExample) |
| TW (1) | TWI386417B (enExample) |
| WO (1) | WO2007072997A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004063221A1 (ja) | 2002-12-26 | 2004-07-29 | Takeda Pharmaceutical Company Limited | メタスチン誘導体およびその用途 |
| US7754220B2 (en) | 2003-03-12 | 2010-07-13 | Takeda Pharmaceutical Company Limited | Methods of inhibiting secretion of follicle-stimulating hormone and testosterone |
| WO2006001499A2 (en) | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) * | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
| US20110118172A1 (en) * | 2008-04-24 | 2011-05-19 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| WO2010013762A1 (ja) | 2008-07-30 | 2010-02-04 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| GEP20146001B (en) * | 2008-12-29 | 2014-01-10 | Takeda Pharmaceuticals Co | Cancer prophylactic/therapeutic agent |
| MX2012006441A (es) * | 2009-12-22 | 2012-06-28 | Takeda Pharmaceutical | Formulacion de liberacion sostenida. |
| EP2585091B1 (en) | 2010-06-25 | 2014-09-10 | Takeda Pharmaceutical Company Limited | Sustained-release formulation comprising a metastin derivative |
| EP2755690B1 (en) | 2011-08-04 | 2020-04-01 | Merck Sharp & Dohme B.V. | Kisspeptide-pentasaccharide conjugates |
| EP2873455B1 (en) | 2012-07-12 | 2021-07-07 | Takeda Pharmaceutical Company Limited | Method for manufacturing microcapsule powder |
| WO2015112703A1 (en) * | 2014-01-22 | 2015-07-30 | The Johns Hopkins University | Compositions and methods for treating diabetes |
| JP6253146B2 (ja) * | 2014-02-04 | 2017-12-27 | 国立大学法人山口大学 | 新規なペプチド誘導体及びこれを含有する医薬 |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| CA3038865A1 (en) * | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating female infertility |
| CN116813705A (zh) * | 2017-07-05 | 2023-09-29 | 凯惠科技发展(上海)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| WO2025217074A1 (en) * | 2024-04-08 | 2025-10-16 | Radionetics Oncology, Inc. | Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
| MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
| CA2229201A1 (en) | 1995-10-19 | 1997-04-24 | Satoshi Sasaki | Quinoline derivatives, their production and use |
| AU2382097A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| MXPA01013367A (es) | 1999-06-28 | 2002-07-02 | Basf Ag | Metodo para la prevencion del crecimiento tumoral. |
| EP1200553B1 (en) | 1999-08-02 | 2009-07-15 | Archer-Daniels-Midland Company | Metabolic engineering of amino acid production |
| AU1889101A (en) | 1999-12-17 | 2001-06-25 | Takeda Chemical Industries Ltd. | Process for producing kiss-1 peptide |
| AU2001261007A1 (en) | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2001075104A1 (fr) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Nouvelle proteine, adn codant pour celle-ci, et son procede de production |
| US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
| JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| WO2002092829A1 (en) | 2001-05-17 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Process for producing peptide |
| DE60219645T2 (de) * | 2001-09-19 | 2007-08-09 | Takeda Pharmaceutical Co. Ltd. | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft |
| AU2003201854A1 (en) * | 2002-01-11 | 2003-07-30 | Takeda Chemical Industries, Ltd. | PROCESS FOR PRODUCING KiSS-1 PEPTIDE |
| JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
| MXPA05004380A (es) | 2002-10-25 | 2005-11-23 | Paradigm Therapeutics Ltd | Mamiferos gpr54 knock out y metodos de investigacion que los utilizan. |
| WO2004063221A1 (ja) | 2002-12-26 | 2004-07-29 | Takeda Pharmaceutical Company Limited | メタスチン誘導体およびその用途 |
| JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| US6800611B2 (en) * | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
| KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Ｌｋ8 단백질을 유효성분으로 포함하는 항암제 |
| US7754220B2 (en) * | 2003-03-12 | 2010-07-13 | Takeda Pharmaceutical Company Limited | Methods of inhibiting secretion of follicle-stimulating hormone and testosterone |
| EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| US20050026224A1 (en) | 2003-04-28 | 2005-02-03 | Follettie Maximillian T. | Methods and compositions for modulating G-protein coupled receptor 54 |
| WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
| WO2004106289A1 (en) | 2003-05-30 | 2004-12-09 | Prozymex A/S | Protease inhibitors |
| RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
| CA2544473C (en) | 2003-11-03 | 2013-08-13 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof |
| WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
| WO2006001499A2 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US7725869B1 (en) * | 2005-04-07 | 2010-05-25 | Xilinx, Inc. | Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description |
| WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
-
2006
- 2006-12-20 AR ARP060105651A patent/AR058584A1/es active IP Right Grant
- 2006-12-20 TW TW095147852A patent/TWI386417B/zh active
- 2006-12-21 PL PL06843555T patent/PL1963362T3/pl unknown
- 2006-12-21 HR HR20110851T patent/HRP20110851T1/hr unknown
- 2006-12-21 NZ NZ568322A patent/NZ568322A/en unknown
- 2006-12-21 WO PCT/JP2006/326176 patent/WO2007072997A1/en not_active Ceased
- 2006-12-21 GE GEAP200610770A patent/GEP20115356B/en unknown
- 2006-12-21 PT PT06843555T patent/PT1963362E/pt unknown
- 2006-12-21 RS RS20110437A patent/RS52007B/sr unknown
- 2006-12-21 AU AU2006328333A patent/AU2006328333B2/en not_active Ceased
- 2006-12-21 RU RU2008125063/04A patent/RU2430107C2/ru active
- 2006-12-21 SI SI200631152T patent/SI1963362T1/sl unknown
- 2006-12-21 ES ES06843555T patent/ES2375038T3/es active Active
- 2006-12-21 EP EP06843555A patent/EP1963362B1/en active Active
- 2006-12-21 KR KR1020087012506A patent/KR101368607B1/ko active Active
- 2006-12-21 ME MEP-2009-175A patent/ME01015B/me unknown
- 2006-12-21 DK DK06843555.1T patent/DK1963362T3/da active
- 2006-12-21 PE PE2006001686A patent/PE20071141A1/es active IP Right Grant
- 2006-12-21 CA CA2634647A patent/CA2634647C/en active Active
- 2006-12-21 JO JO2006486A patent/JO2799B1/en active
- 2006-12-21 US US12/158,251 patent/US7960348B2/en active Active
- 2006-12-21 MY MYPI20082169 patent/MY151967A/en unknown
- 2006-12-21 BR BRPI0619399A patent/BRPI0619399B8/pt not_active IP Right Cessation
- 2006-12-21 JP JP2008529406A patent/JP4653840B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-15 IL IL190888A patent/IL190888A/en active IP Right Grant
- 2008-05-26 CR CR10019A patent/CR10019A/es unknown
- 2008-06-10 NO NO20082595A patent/NO341879B1/no unknown
- 2008-06-18 MA MA31044A patent/MA30060B1/fr unknown
-
2010
- 2010-08-17 JP JP2010182482A patent/JP5298087B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-18 CY CY20111101116T patent/CY1112353T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY151036A (en) | Synthesis of (r)-n-methylnaltrexone | |
| LTC1849470I2 (lt) | Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių | |
| TW200716646A (en) | (S)-N-methylnaltrexone | |
| ZA200709166B (en) | Carrier for targeting nerve cells | |
| WO2008017029A3 (en) | Drug carriers, their synthesis, and methods of use thereof | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| UA101346C2 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды | |
| WO2007061939A3 (en) | Metabolite derivatives of the hdac inhibitor fk228 | |
| IL188896A0 (en) | Diazepinoquinolines, synthesis thereof, and intermediates thereto | |
| CA115145S (en) | Ink cartridge | |
| CY1112877T1 (el) | Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας | |
| WO2008095622A3 (de) | Sekretierte luziferase mluc7 und deren verwendung | |
| CA115126S (en) | Ink cartridge | |
| MX2007005202A (es) | Polisacaridos de estreptococo modificados y usos de los mismos. | |
| TW200619206A (en) | Chemokine-binding heterocyclic compound salts, and methods of use thereof | |
| CA115127S (en) | Ink cartridge | |
| WO2007001962A3 (en) | Systems and methods for generating biological material | |
| CA115124S (en) | Ink cartridge | |
| BRPI0810652A2 (pt) | Gene e proteína reguladores de carbono e nitrogênio e modulação dos mesmos. | |
| SG146640A1 (en) | Isolated photoprotein mtclytin, and use thereof | |
| CA115123S (en) | Ink cartridge | |
| NO20091386L (no) | Fenyloksyanilinderivater | |
| DE602006007777D1 (de) | Reductase Gen und dessen Verwendung | |
| EP1949245A4 (en) | DELIVERING SENSITIVE INFORMATION THROUGH A SECURE RSS SYNDICATION THREAD | |
| TW200716177A (en) | Isolated photoprotein aqdecay, and its use |